Mental health disorders, including anxiety and depression, are increasingly prevalent worldwide, driven by factors such as global instability, the COVID-19 pandemic, and social media. With existing treatments sometimes resulting in unpleasant side effects, there is a pressing need for novel, effective therapies. One such promising candidate is cannabidiol (CBD), which has shown potential in treating various conditions and is now being explored for its benefits in mental health.
Understanding the Rise in Mental Health Disorders
Globally, it is estimated that 5-10% of individuals experience anxiety-related disorders, which significantly impact their quality of life and the broader society. The prevalence of mental health disorders, including anxiety and depression, has surged over the past decade due to various factors, including global instability, the COVID-19 pandemic, and social media. As traditional treatments often come with undesirable side effects, there is a critical need for innovative treatments. CBD may offer a new avenue for addressing these challenges.
CBD’s Promising Role in Mental Health Treatment
CBD, already approved for certain epilepsy syndromes, is being studied for its potential benefits in treating central nervous system diseases and neurological disorders such as Parkinson’s disease and multiple sclerosis. A recent review of CBD’s use in psychiatric disorders found it to be generally safe and well-tolerated, with minimal abuse potential, suggesting its suitability for psychiatric conditions. However, further well-designed longitudinal studies are needed to confirm these findings.
Despite its potential, recent evidence reveals that up to 50% of psychiatric patients using CBD do not report it to their doctors. This highlights both the perceived efficacy of CBD among users and the risks associated with unregulated, low-quality CBD products. Many of these products may contain THC or differ from their labeled composition, underscoring the need for high-quality, regulated CBD therapeutics.
Unlocking CBD’s Full Potential
To maximize the therapeutic potential of CBD, DSM has developed an innovation platform that supports early-stage drug development. Through a strategic partnership with CBD pioneer Brains Bioceutical, DSM offers expertise in developing CBD-based pharmaceuticals, manufactured in an MHRA-approved facility.
With over 70 years of experience in producing and securing quality APIs, DSM is well-positioned to assist innovators in developing high-quality CBD-based therapies. These solutions aim to support mental health and wellbeing on a global scale.
The CBD market holds considerable promise, but successful entry requires more than just quality ingredients—it necessitates a reliable partner.
